Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer

Original Article

C. Vulsteke, N. Adra, P. Danchaivijitr, M. Sabadash, A. Rodriguez-Vida, Z. Zhang, V. Atduev, Y.E. Göger, S. Rausch, S.-H. Kang, Y. Loriot, J. Bedke, M.D. Galsky, P.H. O’Donnell, G.v. Amsberg, N. Alimohamed, G. Sulimka, S. Gupta, V. Paramonov, K. Nakane, M. Mihm, C. Meng, C.D. Huang, C. Ramamurthy, B.H. Moreno, and A. Ullén

N Engl J Med 2026;394:1257-1269

Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit
  • 1.00 Participation
Course opens: 
04/01/2026
Course expires: 
04/02/2028

Available Credit

  • 1.00 AMA PRA Category 1 Credit
  • 1.00 Participation
Please sign in or create an account to take the course.